The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | The movement of BCMA-directed therapies to earlier lines in myeloma treatment
Amrita Krishnan, MD, City of Hope, Duarte, CA, discusses moving BCMA-directed therapies to earlier lines in myeloma treatment. She highlights the need to identify ideal candidates for CAR-T at first relapse and notes that positive results from the DREAMM-7 and DREAMM-8 trials have added antibody-drug conjugates (ADCs) to the treatment options. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
